Insights into the Regulation of Survivin Expression in Tumors
Jiri Vachtenheim* and Katerina Vlckova
Laboratory of Transcription and Cell Signaling, Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University in Prague, Czech Republic
- Corresponding Author:
- Jiri Vachtenheim
Laboratory of Transcription and Cell Signaling
Institute of Medical Biochemistry and Laboratory Diagnostics
Katerinska 32, Prague 2, 12108, Charles University in Prague
First Faculty of Medicine, Czech Republic
E-mail: [email protected]
Received date: Mar 19, 2016; Accepted date: May 30, 2016; Published date: Jun 01, 2016
Citation: Vachtenheim J, Vlckova K (2016) Insights into the Regulation of Survivin Expression in Tumors. Single Cell Biol 5:139. doi:10.4172/2168-9431.1000139
Copyright: © 2016 Vachtenheim J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Survivin, an anti-apoptotic protein was found to be expressed in tumors, whereas in normal tissues the expression of this protein was shown to be absent or extremely low. Survivin exhibits multifunctional activity in tumor cells. Survivin is the smallest member of the inhibitor of apoptosis protein family and was demonstrated to have key roles in regulating cell division and inhibiting apoptosis. The cancer protein survivin was shown to be associated with tumor cell progression, invasiveness, resistance to therapeutics and poor prognosis. Its level in tumors is associated with deregulation of several oncogenic pathways. In this review, a delineation of survivin expression and progress in understanding the survivin transcriptional regulation with the emphasis of augmented apoptosis in cancer and its link to the Hedgehog pathway and cancer stem cells is discussed.